WallStreetZenWallStreetZen

NASDAQ: CFMS
Conformis Inc Stock

$1.11-0.07 (-5.93%)
Updated May 31, 2023
CFMS Price
$1.11
Fair Value Price
$7.85
Market Cap
$8.32M
52 Week Low
$1.05
52 Week High
$10.98
P/E
-0.18x
P/B
0.19x
P/S
0.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$59.34M
Earnings
-$44.01M
Gross Margin
38%
Operating Margin
-70.59%
Profit Margin
-74.2%
Debt to Equity
0.84
Operating Cash Flow
-$43M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CFMS Overview

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CFMS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CFMS ($1.11) is undervalued by 85.86% relative to our estimate of its Fair Value price of $7.85 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CFMS ($1.11) is significantly undervalued by 85.86% relative to our estimate of its Fair Value price of $7.85 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CFMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CFMS due diligence checks available for Premium users.

Be the first to know about important CFMS news, forecast changes, insider trades & much more!

CFMS News

Valuation

CFMS fair value

Fair Value of CFMS stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$7.85
Undervalued by
85.86%
CFMS ($1.11) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CFMS ($1.11) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CFMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CFMS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.18x
Industry
756.76x
Market
54.01x

CFMS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.19x
Industry
3.89x
CFMS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CFMS's financial health

Profit margin

Revenue
$12.8M
Net Income
-$9.6M
Profit Margin
-74.6%
CFMS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CFMS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$81.9M
Liabilities
$37.3M
Debt to equity
0.84
CFMS's short-term assets ($67.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CFMS's short-term assets ($67.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CFMS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CFMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.8M
Investing
-$907.0k
Financing
$0.0
CFMS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CFMS vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
CFMS$8.32M-5.93%-0.18x0.19x
VVOS$8.79M-4.50%-0.37xN/A
SRGA$7.45M+4.92%-0.11x-0.39x
MDGS$7.20M-9.73%-0.73x0.18x
RSLS$7.12M-3.97%-0.03x0.92x

Conformis Stock FAQ

What is Conformis's quote symbol?

(NASDAQ: CFMS) Conformis trades on the NASDAQ under the ticker symbol CFMS. Conformis stock quotes can also be displayed as NASDAQ: CFMS.

If you're new to stock investing, here's how to buy Conformis stock.

What is the 52 week high and low for Conformis (NASDAQ: CFMS)?

(NASDAQ: CFMS) Conformis's 52-week high was $10.98, and its 52-week low was $1.05. It is currently -89.89% from its 52-week high and 5.71% from its 52-week low.

How much is Conformis stock worth today?

(NASDAQ: CFMS) Conformis currently has 7,495,960 outstanding shares. With Conformis stock trading at $1.11 per share, the total value of Conformis stock (market capitalization) is $8.32M.

Conformis stock was originally listed at a price of $481.25 in Jul 1, 2015. If you had invested in Conformis stock at $481.25, your return over the last 7 years would have been -99.77%, for an annualized return of -58% (not including any dividends or dividend reinvestments).

How much is Conformis's stock price per share?

(NASDAQ: CFMS) Conformis stock price per share is $1.11 today (as of May 31, 2023).

What is Conformis's Market Cap?

(NASDAQ: CFMS) Conformis's market cap is $8.32M, as of Jun 1, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Conformis's market cap is calculated by multiplying CFMS's current stock price of $1.11 by CFMS's total outstanding shares of 7,495,960.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.